3rd APV winter conference 2018 | CN 6718
Individualized Medicines for oral use − visions and challengesVenue
Austria Trend Hotel Congress InnsbruckRennweg 12a
6020 Innsbruck
Phone:+43 512 2115-0
Fax:+43 512 2115-500
E-mail:congress@austria-trend.at
Workshop programme for download
Target groups
The target audience are technicians and scientists who are involved in the pharmaceutical development and manufacturing of solid medicinal products and related medical devices. The addressed topics are important for scientific research, pharmaceutical R&D, manufacturing, packaging and business development.
Objective
Recent advancements in pharmacokinetic profiling, genetics, metabolics and improved knowledge in distinguished medicinal disciplines like paediatrics and oncology foster a patientcentered, fully individual and precise drug treatment in future. There are new fascinating options of drug treatment and medical
care. The remaining question is whether we will have the required drug dosage forms for this ongoing shift of paradigm in modern medicine. Most oral dosage forms are monolithic solid drug carriers like tablets and capsules which hardly offer the required flexible dosing. It is unlikely that pharmaceutical industry will be able to provide monolithic dosage forms at multiple dose strengths for individual drug treatment. Fixed-dose combinations with combinations of several drug substances and numerous dose strengths in order to enable precise and patientcentered drug treatment will not be feasible due to technical and
financial constraints.
This hot-topic seminar, organized by APV’s new task force “Individual Medicines”, is embedded in APV’s winter conference series. It will tackle obstacles such as biopharmaceutical and regulatory evaluations of flexible dosing systems, but offer some recent ideas and products to approach the future in oral medicines.
Speaker
Prof. Dr. Jörg Breitkreutz
Jörg Breitkreutz is a pharmacist by training and finished his PhD in 1996 at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under supervision of Prof. Gröning. From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, and from 1997 to 2004 the
University of Münster to work on his habilitation on paediatric drug formulations. In 2004 he became professor for pharmaceutical technology at the Heinrich-Heine-University in Düsseldorf, Germany. Since 2010 he is the president of the International Association of Pharmaceutical Technology (APV).
His research focuses on paediatric drug formulations, orphan drugs and process analytical technologies.
Dr. Elke Sternberger-Rützel
Elke Sternberger-Rützel studied pharmacy at the FU Berlin and Eberhard-Karls-Universität Tübingen until 1998. Thereafter she started 1998 to earned her doctorate in Pharmaceutical Technology at the Karl Ruprecht University Heidelberg. She is also a pharmacist specializing in pharmaceutical technology.
After completing her doctorate, she worked in the pharmaceutical development department of Grünenthal GmbH (2002-2006) as laboratory manager for packaging development, stability studies and packaging of clinical test samples. Later in the R & D department of Catalent Pharma Solution (Schorndorf, Germany) (2006-2009) as a packaging developer with a focus on microdosing, as interim head of department and project manager. Subsequently, she was hired as Pharma Trendscout and Innovation Manager at Robert Bosch Gmbh Packaging Pharma (2009-2012). Since 2013 she has been working for Harro Höfliger GmbH as Head of Test Facilities within Pharma Services.
Registration fee
| 15.12.2017 | 16.12.2017 | |
|---|---|---|
| Industry | 1,290.00 € | 1,490.00 € |
| Authorities/Academia | 645.00 € | 745.00 € |
| Students (full time) | 155.00 € | 178.00 € |
Organizer(s)
APV-Office
Dr. Martin Bornhöft
Phone: +49 6131 9769-0
Fax: +49 6131 9769-69
E-mail: apv@apv-mainz.de
www: https://www.apv-mainz.de/